Virpax Pharmaceuticals Financials
| VRPX Stock | USD 0.59 0.03 4.84% |
Virpax |
Understanding current and past Virpax Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Virpax Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Virpax Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Virpax Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Virpax Pharmaceuticals. Check Virpax Pharmaceuticals' Beneish M Score to see the likelihood of Virpax Pharmaceuticals' management manipulating its earnings.
Virpax Pharmaceuticals Stock Summary
Virpax Pharmaceuticals competes with Revelation Biosciences, Palisade Bio, Virax Biolabs, Quoin Pharmaceuticals, and RenovoRx. Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania. Virpax Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.Specialization | Healthcare, Biotechnology |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US9282511073 |
| CUSIP | 928251107 928251206 |
| Location | Pennsylvania; U.S.A |
| Business Address | 1055 Westlakes Drive, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.virpaxpharma.com |
| Phone | 610 727 4597 |
| Currency | USD - US Dollar |
Virpax Pharmaceuticals Key Financial Ratios
| Return On Equity | -3.62 | ||||
| Return On Asset | -0.91 | ||||
| Target Price | 3.0 | ||||
| Beta | 1.1 |
Virpax Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Virpax Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Virpax Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Virpax Pharmaceuticals competition to find correlations between indicators driving Virpax Pharmaceuticals's intrinsic value. More Info.Virpax Pharmaceuticals is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Virpax Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Virpax Pharmaceuticals Systematic Risk
Virpax Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Virpax Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Virpax Pharmaceuticals correlated with the market. If Beta is less than 0 Virpax Pharmaceuticals generally moves in the opposite direction as compared to the market. If Virpax Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Virpax Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Virpax Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Virpax Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Virpax Pharmaceuticals is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Virpax has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Virpax Pharmaceuticals' financials are consistent with your investment objective using the following steps:- Review Virpax Pharmaceuticals' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Virpax Pharmaceuticals' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Virpax Pharmaceuticals' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Virpax Pharmaceuticals' stock is overvalued or undervalued.
Virpax Pharmaceuticals Thematic Clasifications
Virpax Pharmaceuticals is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
| Pharmaceutical Products | View |
Virpax Pharmaceuticals November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Virpax Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Virpax Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Virpax Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Virpax Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Virpax Pharmaceuticals's daily price indicators and compare them against related drivers.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 44.98 | |||
| Value At Risk | (8.33) | |||
| Potential Upside | 10.96 |
Additional Tools for Virpax Stock Analysis
When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.